publications GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications May 27, 2025 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice...

Someone holds a GLP-1 pen needle in their hands.

New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more

Novo Nordisk’s semaglutide (Wegovy) recently received a U.S. Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first...

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

publications Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development July 31, 2025 Editor-in-chief's message Welcome to Prime...

publications Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development April 25, 2025 Editor-in-chief's message Welcome to the Prime...

cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...